Recommended Pages at drug-injury.com
Medical Journal Withdraws Article About Januvia And Byetta After It Gets Letters From Two Drug Companies - Drug Injury Watch
drug-injury.com — “April 2011 Edition Of BMJ Breaks News And Provides Insight From One Who Saw An Increased Risk Of Pancreatitis (Posted by Tom Lamb at DrugInjuryWatch.com) According to a news item published April 11, 2011 by The British Medical Journal (BMJ), letters written by Merck and Novo Nordisk to Anil Rustgi, the editor-in-chief of Gastroenterology, resulted in that journal withdrawing an article which it had posted on its website about how Januvia (sitagliptin) and Byetta (exenatide) have been associated ” View full resource at drug-injury.com
Most Recently Shared on May 3, 2011 at 3:20 pm By:
Dr Kelly Sennholz Physician, Doctor, Internist, and Emergency Physician
RT @soulflsepulcher @TomLamb Med Journal W/draws Article About Januvia & Byetta After It Gets Letters From 2 Drug Cos http://bit.ly/lt15Cr
Pfizer's "Witness Tampering" Motion in Neurontin Case Is Denied (Drug Injury News Reports)
drug-injury.com — “Quoted from http://industry.bnet.com/pharma/10004813/pfizers-witness-tampering-motion-in-neurontin-case-is-denied/ Pfizer's "Witness Tampering" Motion in Neurontin Case Is Denied By Jim Edwards | Oct 14, 2009 A federal judge has ruled against Pfizer's request for sanctions against a witness in the Neurontin litigation whom it alleged had attempted to wrongly influence another witness in the case. The judge dismissed Pfizer's allegations with just four words: This Motion is DENIED. Down” View full resource at drug-injury.com
Most Recently Shared on October 15, 2009 at 9:05 pm By:
Jennifer Ann Grisso Nurse and Active Health Library
RT @TomLamb: Pfizer's "Witness Tampering" Motion in Neurontin Case Is Denied http://bit.ly/1vmAcw remember movie"the insider"?
Cancer, bowel drugs on U.S. FDA safety scrutiny list (Drug Injury News Reports)
drug-injury.com — “Quoted from http://www.reuters.com/article/marketsNews/idCNN0749040120091007?rpc=44 Cancer, bowel drugs on U.S. FDA safety scrutiny list WASHINGTON, Oct 7 (Reuters) - More than a dozen drugs including a cancer therapy and a bowel medicine are under early scrutiny for potential side effects, U.S. regulators said in a quarterly list released on Thursday. The Food and Drug Administration said it was investigating cases of liver failure in patients treated with Pfizer Inc's cancer drug Sutent. The a” View full resource at drug-injury.com
Most Recently Shared on October 8, 2009 at 12:56 pm By:
eyeonfda Pharma and Health Lawyer
RT @TomLamb: Cancer, bowel drugs on U.S. FDA safety scrutiny list http://bit.ly/1005rt
Asthma Drug Xolair Is Being Investigated By FDA For Possible Cardiac Problems - Drug Injury Watch
drug-injury.com — “Serious Side Effects Include Heart Attacks, Abnormal Heart Rhythms, Heart Failure, And Various Conditions Caused By Blood Clots (Posted by Tom Lamb at DrugInjuryWatch.com) By means of a July 16, 2009 MedWatch Email Alert we first learned about an ongoing FDA investigation of Xolair (omalizumab): FDA is evaluating interim safety findings from an ongoing study of Xolair (omalizumab) titled Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS” View full resource at drug-injury.com
Most Recently Shared on September 23, 2009 at 12:28 am By:
Frederick Schurger, DC Chiropractor, Doctor, and CAM
Asthma Drug Xolair Is Being Investigated By FDA For Possible Cardiac Problems http://bit.ly/C1DPq
